[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"PeriPharm\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":61},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100617805","real-world-study-on-the-impact-of-atopic-dermatitis-from-a-caregiver-perspective-100617805",false,"NCT07323394","Real-World Study on the Impact of Atopic Dermatitis From a Caregiver Perspective","Inclusion Criteria:\n\n1. Aged ≥18 years;\n2. Caregiver of a child aged ≥2 to ≤11 years with mild to moderate atopic dermatitis;\n3. Able to read and understand French or English;\n4. Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n1. Caregivers whose child has been diagnosed with severe atopic dermatitis ;\n2. Caregivers whose child is currently treated with oral or topical Janus Kinase Inhibitor);\n3. Caregivers whose child is currently participating in a clinical trial for atopic dermatitis;\n4. Other parent or caregiver within the household of the child with atopic dermatitis.",true,"ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","OBSERVATIONAL","This study will address this gap by providing comprehensive data on disease burden from a caregiver perspective in a Canadian population, ultimately supporting improved clinical decision-making and healthcare resource allocation.",[24,25,26,27,28],"Atopic Dermatitis","Eczema Atopic Dermatitis","Eczema","Caregiver","Burden",[30,31,32],"atopic dermatitis","quality of life","real-world","NOT_YET_RECRUITING","2026-01-22",{"date":36,"type":37},"2026-01-23","ACTUAL",{"date":39,"type":20},"2026-01",{"date":41,"type":20},"2026-07",{"name":43,"class":44},"PeriPharm","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":59,"leadSponsor":60,"locationsCount":4},"100617798","real-world-study-on-the-burden-of-hidradenitis-suppurativa-100617798","NCT07323303","Real-World Study on the Burden of Hidradenitis Suppurativa","Inclusion Criteria:\n\n1. Patient diagnosed with HS;\n2. Aged ≥18 years;\n3. Able to read and understand French or English;\n4. Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n1\\. Participation in an interventional study for HS.",{"count":19,"type":20},"Despite the significant impact of HS on patients' quality of life (QoL) and daily functioning, there remains limited real-world evidence describing the burden of this condition in Canada. HS is an under-recognized and often misdiagnosed condition, with a substantial psychological and physical burden on patients. Understanding the real-world experiences of individuals living with HS in Canada can help identify unmet needs and inform patient-centered care approaches.",[54],"Hidradenitis Suppurativa (HS)","2025-12-22",{"date":57,"type":37},"2026-01-07",{"date":39,"type":20},{"date":41,"type":20},{"name":43,"class":44},""]